ArticleClinical case reports2025
Black Hairy Tongue as a Rare Adverse Effect of Linezolid in Multidrug-Resistant Tuberculosis: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Black Hairy Tongue as a Rare Adverse Effect of Linezolid in Multidrug-Resistant Tuberculosis: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Black hairy tongue (BHT), or lingua villosa nigra, is a rare adverse effect of linezolid, an antibiotic frequently used in the treatment of multidrug-resistant tuberculosis (MDR-TB). We present a case of a 24-year-old female who developed BHT while receiving linezolid as part of a longer regimen for MDR-TB. The patient exhibited a typical BHT presentation, with painless brown-to-black discoloration on the posterior dorsal surface of her tongue, appearing 25 days after initiating linezolid therapy. There were no other identifiable contributing factors. Upon discontinuation of linezolid and a shift to a modified regimen, the BHT completely resolved within 10 days. A Naranjo Adverse Drug Reaction Probability Scale score of 5 suggested a probable causal relationship between linezolid and BHT. This report represents the first documented case of linezolid-associated BHT from Nepal, highlighting the importance of clinicians' awareness of this rare but clinically significant side effect, especially within the context of MDR-TB treatment, to provide prompt diagnosis, reassurance, and appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.